The ECJ GSK Ruling: everyone’s a winner baby, that’s the truth...
This article was originally published in RAJ Devices
Executive Summary
The recent Ruling from the European Court of Justice (ECJ) in the GlaxoSmithKline (GSK) v. Greek wholesalers case has unsurprisingly been greeted by both sides as a partial victory. The Ruling, which essentially prevents a pharmaceutical company from restricting supplies in order to destroy parallel trade involving its product – unless the demands of the wholesaler/parallel trader are deemed “out of the ordinary”, is on the face of it a judgement that indeed easily lends itself to ambiguity.
You may also be interested in...
MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins
In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.
EMA Acts To Freeze GVK Drugs, Guard Against Shortages
The EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.
EMA Acts To Freeze Drugs Linked to GVK Bio, Guards Against Shortages
EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.